The senior management currently consists of the CEO, CFO, CSO, Head of Regulatory Affairs, COO, Head of Research and CMC, CMO, CCO, President North America, General Counsel and Global Head of Corporate Communications.
MARTY J DUVALL
Chief Executive Officer
Marty J Duvall was appointed as CEO in 2020.
Marty has extensive experience from executive leadership roles in drug development and commercialization within the global biotechnology and pharmaceutical industry, including a unique experience from the oncology and hematology sphere.
Prior to joining Oncopeptides Marty was Chief Executive Officer of Tocagen Inc. Previously he served as Executive Vice President, Chief Commercial Officer of ARIAD pharmaceuticals, and led the company’s transformation into a fully integrated, global biotechnology company. Marty has been Senior Vice President and General Manager, oncology, at Merck & Co., Inc. Earlier he was Senior Vice President, global marketing and commercial operations at Abraxis Bioscience, Inc. and Senior Vice President, commercial operations, for MGI Pharma. He has held several commercialization, marketing and sales roles in oncology at Sanofi.
Marty holds a MA in chemistry from Johns Hopkins University, an MBA from the University of Kansas, and a BS in chemistry from Muhlenberg College.
Holdings in Oncopeptides: 243,212 options**.
Other Current positions: Chairman of Oncopeptides Inc.
ANDERS MARTIN-LÖF, MSc
Chief Financial Officer
Anders Martin-Löf was appointed CFO in 2018 and is responsible for Finance, IR, HR, IT & Administration.
Anders was previously CFO of Wilson Therapeutics AB and RaySearch Laboratories AB, both listed on Nasdaq Stockholm. He held various business development positions for Swedish Orphan Biovitrum where he also served as Director of Investor Relations. In addition he has worked as a management consultant at the Boston Consulting Group, Cell Network and as co-founder and CEO of ScienceCap.
Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BA in Business Administration and Economics, from Stockholm University.
Holdings in Oncopeptides: 5,000 shares and 248,576 options**.
Other current positions: Director of Cantargia AB and alternate director of Lisa Martin-Löf konsultbyrå AB and alternate director of Oncopeptides Incentive AB.
JAKOB LINDBERG, Med Lic
Chief Scientific Officer, CSO
Jakob Lindberg was appointed as CSO in 2020.
In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB.
Jakob was CEO of Oncopetides AB between 2011 and 2020. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.
Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.
Holdings in Oncopeptides: 560,831 shares (545,531 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 175 employee options* and 315,423 options**.
Other current positions: Director of Affibody Medical AB and Lindberg Life-Science AB. Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.
EVA NORDSTRÖM, MSc Pharm
Vice President, Chief Operating Officer
Eva Nordström was appointed as Head of Clinical Development in 2012 and Chief Operating Officer 2020. Eva is responsible for strategic and operational deliveries in Biostatistics, Clinical Operations, Data Management, Global Drug Supply and Project & Process Management.
Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.
Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.
Holdings in Oncopeptides: 120,200 shares, 33 employee options* and 132,671 options**.
Other current positions: Alternate Director of Utilica AB.
FREDRIK LEHMANN, PhD
Head of Research and CMC (Chemistry, Manufacturing & Control)
Fredrik Lehmann was appointed Head of CMC in 2010 and Head of Research in 2018.
In addition to being Head of CMC for Oncopeptides, Fredrik is an independent consultant within preclinical research and CMC.
Fredrik has previously held positions at a number of life sciences businesses including Pharmacia, Personal Chemistry, Biovitrum and Recipharm. He has also co-founded six life science companies.
Fredrik holds a PhD in medicinal chemistry from Gothenburg University.
Holdings in Oncopeptides: 17,652 shares (16,652 directly owned, 1,000 indirectly owned through OT Lehmann Holding AB), 13 employee options* and 92,389 options**.
Other current positions: Director and CEO of OT Pharmaceuticals AB. Board member of OT Lehmann Holding AB and Chariman of the board of Synartro AB. Board member of Sprint Bioscience and member of the Scientific Advisory Board at Akthelia Pharmaceuticals.
JOSEPH HORVAT, BSc
President North America
Joseph Horvat was appointed President North America in 2019.
Before Joseph joined Oncopeptides, he served for nine years in different positions at EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany), most recently as Senior Vice President of the Oncology Business Unit with responsibility for driving the US oncology product portfolio. He previously played a critical role in the development of EMD Serono’s commercial build up in antizipation of an upcoming launch. As part of his responsibility, Joseph created a strong culture and attracted talent that incrementally added to the success of the franchise and set the foundation for EMD Serono’s launch of its first immuno-oncology product.
Prior to joining EMD Serono, Joseph spent over a decade of his early career at Bristol-Myers Squibb where he held various roles of increasing responsibility across several areas including oncology, cardiovascular and neuroscience.
Holdings in Oncopeptides: 146,038 options**.
KARIN EKLUND VANDERPOL, MSc Pharm
Head of Regulatory Affairs
Karin Eklund Vanderpol was appointed Head of Regulatory Affairs in 2020.
Prior to joining Oncopeptides, Karin worked at Swedish Orphan Biovitrum (Sobi) where she held different positions, most recently Global Regulatory Affairs Director, Haemophilia. In this role she contributed to the approvals and launches of important new haemophilia products in Europe and other markets.
Previously, Karin worked at Astra Zeneca, in different roles within Regulatory Affairs.
Karin holds a MSc Pharm from Uppsala University.
Holdings in Oncopeptides: –
KAROLINA VILVAL, LL.M.
Karolina was appointed General Counsel in 2020.
Karolina has been active as a Legal Counsel in the pharmaceutical industry for the past 15 years.
Prior to joining Oncopeptides, Karolina worked at Gilead Sciences, Nordic affiliates as Associate Legal Director.
Previously, Karolina has worked at Biovitrum and Swedish Orphan Biovitrum (Sobi) in various positions in Legal Affairs.
Karolina holds a law degree from Stockholm University.
Holdings in Oncopeptides: 6,916 options**.
KLAAS BAKKER, MD, PhD
EVP and Chief Medical Officer
Klaas Bakker was appointed as Chief Medical Officer in 2019 and is responsible for Clinical Development Strategy, Pharmacovigilance/Patient Safety, Medical Affairs and Compliance.
Klaas has previously held roles with increasing seniority at AstraZeneca, most recently as Vice President Medical Affairs of the Global TAGRISSO/TDR Franchise in Oncology. In this role he was responsible for the global launch of osimertinib, the companies‘ largest asset across all therapeutic areas.
Klaas holds an MD and is a board certified neurosurgeon from the university of Groningen, the Netherlands, where he was clinically active until 2015. In addition, he holds a PhD in Hematology and has authored over 40 publications in international peer-reviewed journals.
Holdings in Oncopeptides: 7,500 shares and 87,356 options**.
Chief Commercial Officer
Paula Boultbee was appointed as the Chief Commercial Officer in 2016.
Paula comes with expertise that is acquired from both small and large pharmaceutical companies, most recently she was the Executive Vice President of Sales and Marketing at Pharmacyclics where she did build a team and launched their first commercial product, Imbruvica that has become a multi-billion dollar asset. She has also held positions at Novartis, Amgen and Pharmacia with growing responsibility in both sales, brand management, country and regional leadership roles; Novartis as Executive Director a leader and executer for a global launch of flagship product Glivec/Gleevec (imatinib) with $6Billon global sales.
Before joining Oncopeptides she worked as independent consult and has supported several companies in building their commercial markets that have led to successful launch, fundraising, desired acquisitions and licensing agreements.
Paula has nursing degree.
Holdings in Oncopeptides: 160,415 options**.
Other current positions: Chairman of The Max Foundation and Isofol Medical AB board member. Advisor to Monocl AB and early stage biotech companies in the Bay Area California. Paula runs PTB Consulting LLC.
Head of Global Corporate Communications
Rolf Gulliksen was appointed as Head of Global Corporate Communications in 2020. Rolf is responsible for building an integrated corporate communications function, and developing and executing a global communications strategy.
Rolf has an extensive background in strategic communication for life science industry and consultancy. Previous positions include Head of Corporate Communications at Hansa Biopharma, SVP Corporate Communications Biovitrum, Corporate Affairs Director Pfizer, VP Public Affairs and Communications Pharmacia in EMEA, and External Affairs Manager at MSD. He has also headed the life science business at leading communication agencies; Hallvarsson and Halvarsson Group, Springtime, InVivo, and Edelman.
Rolf has studied chemistry, biology, physics, geology pedagogy and methodology at Uppsala University.
Holdings in Oncopeptides: –
Other current positions: CEO and Senior Advisor, Gulliksen Strategic Relations AB
* Each employee option entitles the holder to acquire 900 shares per option in the company.
** The options entitles to one share per option in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.
Holdings in Oncopeptides AB as of July 9, 2020.